title: Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.
abstract: OBJECTIVE
  This survey of Italian psychiatrists was conducted to better define drivers of schizophrenia treatment choice in real-life practice, particularly for use of long-acting injectable (LAI) antipsychotics.
  
  
  METHODS
  Between October 15 and December 15, 2014, 1,000 surveys were sent to psychiatrists who treat schizophrenic patients; 709 completed questionnaires were analyzed (71% response rate).
  
  
  RESULTS
  The two most important factors determining therapy success were efficacy (75% of responses) and tolerability (45%) followed by global functioning (24%) and quality of life (17%). LAI antipsychotics were most often used to facilitate regular treatment monitoring (49%), and 41% of psychiatrists thought that patients with low adherence who had failed oral therapy were well-suited for LAI antipsychotics. Only 4% of respondents saw LAI antipsychotics as appropriate for patients without other therapeutic options.
  
  
  CONCLUSIONS
  Although efficacy and tolerability were the most common factors used to evaluate treatment success in schizophrenia, psychiatrists also consider QoL and global functioning to be important.
authors.affiliation: Section of Psychiatry and Treatment Resistant Psychosis, Department of Neuroscience, University of Naples Federico II, Naples, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: de Bartolomeis
authors.affiliation: Department of Molecular and Developmental Medicine, School of Medicine, University of Siena, Siena, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Fagiolini
authors.affiliation: Mental Health and Drug Addiction Department, Genovese, Genoa, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Vaggi
authors.affiliation: Department of Mental Health, Ospedale Civile Maggiore and ULSS 20, Verona, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Vampini
keywords: long-acting injectable antipsychotics; quality of life; schizophrenia; survey
references.citation: Med Care. 1998 May;36(5):752-6
references.pmid: 9596066
references.citation: Expert Opin Pharmacother. 2010 Oct;11(14):2301-17
references.pmid: 20586707
references.citation: Schizophr Res. 2012 Feb;134(2-3):219-25
references.pmid: 22154594
references.citation: PLoS One. 2012;7(5):e37087
references.pmid: 22615901
references.citation: Curr Psychiatry Rep. 2006 Aug;8(4):329-34
references.pmid: 16879798
references.citation: Qual Life Res. 2011 Mar;20(2):263-72
references.pmid: 20922485
references.citation: World Psychiatry. 2009 Feb;8(1):35-6
references.pmid: 19293958
references.citation: Nord J Psychiatry. 2013 Jun;67(3):153-8
references.pmid: 22587635
references.citation: Eur Neuropsychopharmacol. 2004 Nov;14 Suppl 4:S435-44
references.pmid: 15572262
references.citation: Psychiatry Res. 2013 Mar 30;206(1):62-7
references.pmid: 23021423
references.citation: J Clin Psychiatry. 2014;75 Suppl 2:30-3
references.pmid: 24919169
references.citation: Schizophr Res. 2009 Sep;113(2-3):246-51
references.pmid: 19595578
references.citation: Psychiatr Q. 2014 Sep;85(3):357-67
references.pmid: 24789610
references.citation: Patient Prefer Adherence. 2013 Nov 13;7:1171-80
references.pmid: 24265549
references.citation: J Clin Psychiatry. 2008;69 Suppl 3:4-10
references.pmid: 18533756
references.citation: Psychol Assess. 2014 Sep;26(3):980-9
references.pmid: 24796341
references.citation: Ned Tijdschr Geneeskd. 2010;154:A1874
references.pmid: 20456790
references.citation: World J Biol Psychiatry. 2013 Feb;14(1):2-44
references.pmid: 23216388
references.citation: Health Qual Life Outcomes. 2012 Jun 07;10:61
references.pmid: 22676639
references.citation: Ther Adv Psychopharmacol. 2013 Apr;3(2):89-99
references.pmid: 24167680
references.citation: Dialogues Clin Neurosci. 2014 Jun;16(2):185-95
references.pmid: 25152657
references.citation: Schizophr Res. 1991 Oct;5(3):249-53
references.pmid: 1684722
references.citation: Psychiatr Danub. 2014 Mar;26(1):2-11
references.pmid: 24608146
references.citation: Eur Psychiatry. 2012 Jan;27(1):9-18
references.pmid: 21561742
references.citation: Am J Psychiatry. 2011 Jun;168(6):603-9
references.pmid: 21362741
references.citation: Schizophr Res. 2009 May;110(1-3):1-23
references.pmid: 19328655
references.citation: Health Qual Life Outcomes. 2012 Apr 02;10:35
references.pmid: 22472127
references.citation: BMC Psychiatry. 2013 Dec 20;13:340
references.pmid: 24359031
references.citation: Int J Soc Psychiatry. 1999 Winter;45(4):268-75
references.pmid: 10689610
references.citation: J Clin Psychiatry. 2013 Sep;74(9):e18
references.pmid: 24107769
references.citation: Schizophr Bull. 2007 Sep;33(5):1138-48
references.pmid: 17493956
references.citation: Eur Neuropsychopharmacol. 1998 Feb;8(1):55-66
references.pmid: 9452941
references.citation: Soc Sci Med. 1998 Jun;46(12):1569-85
references.pmid: 9672396
references.citation: Schizophr Res. 2010 Sep;122(1-3):1-23
references.pmid: 20655178
references.citation: Psychiatr Danub. 2010 Dec;22(4):495-7
references.pmid: 21169888
references.citation: Nurs Res. 1994 Jul-Aug;43(4):196-202
references.pmid: 8047422
references.citation: Ann Gen Psychiatry. 2011 Mar 11;10:6
references.pmid: 21396102
references.citation: Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
references.pmid: 15000267
references.citation: J Clin Psychiatry. 2006 Mar;67(3):453-60
references.pmid: 16649833
references.citation: Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219
references.pmid: 25360245
references.citation: Psychiatry Clin Neurosci. 2008 Aug;62(4):404-11
references.pmid: 18778437
references.citation: Encephale. 2012 Apr;38(2):111-7
references.pmid: 22516268
references.citation: Patient Relat Outcome Meas. 2014 Jun 23;5:43-62
references.pmid: 25061342
references.citation: Semin Oncol. 1995 Apr;22(2 Suppl 3):73-81
references.pmid: 7537908
references.citation: Int Clin Psychopharmacol. 2012 Nov;27(6):336-49
references.pmid: 22859065
references.citation: Lancet. 2009 Aug 22;374(9690):635-45
references.pmid: 19700006
references.citation: Schizophr Res Treatment. 2012;2012:318535
references.pmid: 22966433
references.citation: Curr Opin Psychiatry. 2008 Nov;21(6):630-9
references.pmid: 18852573